SonoVascular, Inc. just raised $6M in Series A first close, and no, this is not one of those polite golf claps the market gives out of habit. This one has resonance. Literal and financial. Harbright...
SonoVascular, Inc. just raised $6M in Series A first close, and no, this is not one of those polite golf claps the market gives out of habit. This one has resonance. Literal and financial. Harbright Ventures led the round, and Robert Ross stepped onto the board, which tells you this is not tourist capital. This is conviction money that reads the room before the room knows it is being read.
Daniel Estay, CEO, did not stumble into this company. Daniel Estay went hunting for it. In 2017, while most people were skimming headlines, Daniel Estay was reading a vascular medicine journal and caught a signal coming out of the Joint Department of Biomedical Engineering at UNC Chapel Hill and NC State University. He followed the sound, licensed the technology through NC State’s Office of Research Commercialization in 2018, and built SonoVascular, Inc. with the patience of someone who has already seen how medical devices actually survive the real world.
The product carries the same energy. The SonoThrombectomy System does not posture. It works. Ultrasound energy, microbubbles, low-dose thrombolytic delivery, and mechanical removal, all meeting at the clot through the RESONATOR catheter. 1 session. 0 blood loss. 0 vascular trauma. Venous valves preserved. ICU stays taken out of the equation. It treats deep vein thrombosis without making the physician choose between clearing clot and damaging the vessel. That trade-off has been tolerated for decades. SonoVascular, Inc. decided to retire it.
Clinical data is where the volume goes up. 10 patients treated in the first-in-human study for DVT. 100% Marder score reduction across the board, adjudicated by an independent core lab. 0 device-related adverse events. Sustained improvement at 30-day and 6-month follow-ups. That is not optimism. That is evidence.
Luke Harada, COO, brings the operational spine, Kevin Holbrook, VP R&D, brings decades of device development scar tissue, and the board is stacked with builders who have shipped, exited, and done it again. Bill Starling does not sit quietly. Ken Gall does not miss. Robert Ross joining now is timing, not coincidence.
Venous thromboembolism hits up to 900,000 patients a year in the United States alone. 33%–50% of DVT patients develop post-thrombotic syndrome. Pulmonary embolism still takes lives within weeks. SonoVascular, Inc. is not chasing noise. It is lowering it, using sound to clear what blocks flow, and reminding the market that disciplined science, real data, and patient capital still move faster than hype when they are tuned correctly.